Botensilimab plus balstilimab for metastatic heavily pretreated microsatellite stable colorectal...

Dr Andrea Bullock speaks to ecancer as part of WCGIC 2023 about a phase I study she presented evaluating botensilimab, a multifunctional anti-CTLA-4, plus balstilimab for metastatic heavily pretreated microsatellite stable colorectal cancer.

She explains that 101 microsatellite stable colorectal cancer patients were enrolled and treated with the combination with 87 patients identified as efficacy evaluable.

Dr Bullock reports that among the 87 efficacy evaluable patients, 18% had a confirmed objective response which translated into a 12 month overall survival estimate of 62% in the total population.